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Dear Editor,
As some problems have been mentioned in article 
"Should We Rely on the Findings of Each Published Ran-
domized Controlled Study?" (1), this letter has been pro-
vided to clarify them for journal's readerships.
Nowadays, Randomized Clinical Trial studies have been 
known as gold standard studies on condition that re-
searchers pay attention on the most important factors in 
design such as:
1. Maximize statistical power in equal group sizes espe-
cially in subgroup analyses.
2. Minimize selection bias when randomization pro-
cedure will be unpredictable so that researchers cannot 
guess the next subject's group assignment based on prior 
treatment assignments. Also it is noticeable that balanc-
ing both known and unknown prognostic factors in the 
assignment of treatments is basic to approve it.
3. Minimize allocation bias when the treatment effect is 
confounded with the effect of the covariates.
4. Rectify statistical error of RCTs that contains both 
type I ("false positive") and type II ("false negative") (2-5).
It should be noted there are some other points in these 
studies that are in the second priorities, which can im-
prove results, but it is conventional like biostatistics pro-
cedures. Many consider T test, ANOVA, and Chi Square 
test were developed over more than 60 years ago and 
the statistical methodology has been advanced. While 
these tests may still be appropriate, it is likely that ad-
ditional statistical analysis will be considered as re-
quired analysis by many peer reviewers of journals (6). 
If we are interested in measuring dependent variables 
at the beginning and the end of the study at least twice 
and to compare treatment groups, not just looking at 
whether there has been any time dependent change in 
each group of subjects, we would have a multivariate 
repeated measurement especially when experimental 
hypotheses are stated in main topic rather than simply 
main effects or interactions. This statistical analysis is 
able to determine that there is a change in the variables 
levels of subjects over time (time effect) within-subjects, 
treatment effect between-subjects and the effect of time 
the same for both treatments. Therefore, with regarding 
to these advantages, authors are keen on using repeated 
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measures in this study. Sometimes investigators detect 
effects in their experiment that were not expected or de-
cide to explain almost any pattern of means, it would be 
appropriate to analyze and evaluate that pattern as mul-
tiple tests post-hoc. However many journals have recom-
mended that mention of post-hoc comparisons should 
be avoided in the text (7). Otherwise, it is obvious that 
researchers have done many statistical analyses such as 
determining normal distribution of variables by valid 
methods or establishing the agreement between observ-
ers and intra-observer but it is not essential to report all 
details providing that journals are captivated to express 
the specific information. It should be noticed this trial 
study like the others is registered in the clinical trial 
registry (IRCT), although the journal does not have any 
tendency to report it. In addition, it should be pointed 
out that cut-off definition of some variables such as ab-
normal FBS or liver function test is health based and is 
associated with progress of metabolic syndrome com-
ponents neither calculate on population percentiles. De-
spite authors have paid careful attention to write results, 
there are some errors. We did not have any missing data 
and Table below shows correct numbers and percent-
ages. Finally authors appreciate everyone who pays at-
tention to our randomized clinical pilot study and offers 
the more attention in design of these studies which can 
lead to achieve the more effective results as we have con-
cerned in this study.
Table. Clinical and Non-Clinical Changes of Some Parameters in Three Groups of Intervention
 
 
HOMA-IR Cholesterol
Pre No. (%) Post No. (%) Pre No. (%) Post No. (%)
Pioglitazone     
Clinical 12 (54.55) 5 (22.73) 11 (50) 7 (31/82)
Non Clinical 10 (45.45) 17 (77.27) 11 (50) 15 (68.18)
Metformin     
Clinical 13 (59.1) 8 (36.36) 9 (40.91) 6 (27.27)
Non Clinical 9 (4. 9) 14 (63.64) 13 (59.09) 16 (72.73)
Silymarin     
Clinical 13 (59.1) 13 (59.1) 10 (45.45) 7 (31.8)
Non Clinical 9 (40.9) 9 (40.9) 12 (54.55) 5 (68.2)
Total     
Clinical 38 (57.6) 26 (39.4) 30 (45.46) 20 (30.3)
Non Clinical 28 (42.4) 40 (60.6) 36 (54.55) 46 (69.7)
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